All In MedTech

FDA Clearance Tracker · P150004-S085

Proclaim Dorsal Root Ganglion (DRG) Neurostimulator System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 13, 2026

Approved

Time to decision

223 days

Received Jun 4, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150004-S085
Device name
Proclaim Dorsal Root Ganglion (DRG) Neurostimulator System
Applicant location
Plano, TX
Received
Jun 4, 2025
Decided
Jan 13, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150004

Device type

Device class
Class III

Every decision under product code PMP

FDA's approval statement

As written in FDA's record.

Approval for expanded MR Conditional labeling to include prone positioning for the Proclaim DRG System.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.